Myasthenia Gravis — Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
Citation(s)
A Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Multi-Center Study of Eculizumab in Patients With Generalized Myasthenia Gravis (gMG) Who Have Moderate to Severe Muscle Weakness Despite Treatment With Immunosuppressants